Financials data is unavailable for this security.
View more
Year on year Meditera Tibbi Malzeme Sanayi ve Ticaret AS 's revenues fell -8.99% from 1.60bn to 1.45bn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 114.34m to 25.87m, a -77.38% decrease.
| Gross margin | 40.31% |
|---|---|
| Net profit margin | -8.88% |
| Operating margin | 15.62% |
| Return on assets | -9.27% |
|---|---|
| Return on equity | -12.08% |
| Return on investment | -11.24% |
More ▼
Cash flow in TRYView more
In 2023, cash reserves at Meditera Tibbi Malzeme Sanayi ve Ticaret AS fell by 11.08m. However, the company earned 139.94m from its operations for a Cash Flow Margin of 9.64%. In addition the company used 1.69m on investing activities and also paid 149.33m in financing cash flows.
| Cash flow per share | -0.7331 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 17.63 |
|---|---|
| Tangible book value per share | 17.62 |
More ▼
Balance sheet in TRYView more
| Current ratio | 3.60 |
|---|---|
| Quick ratio | 2.43 |
| Total debt/total equity | 0.026 |
|---|---|
| Total debt/total capital | 0.0253 |
More ▼
Growth rates in TRY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -76.67% and -77.38%, respectively. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
| EPS growth(5 years) | 15.68 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -11.41 |
